Clinical Benefit of Ropeginterferon Alfa 2b (P1101) in Patients with Myelofibrosis

被引：1
|
作者：
Palmer, Jeanne [1 ]
Kosiorek, Heidi E. [2 ]
Zimmerman, Craig [3 ]
Zagrijtschuk, Oleh [3 ]
Camoriano, John [4 ]
Mesa, Ruben A. [5 ]
机构：
[1] Mayo Clin, Div Hematol & Med Oncol, Dept Med, Phoenix, AZ USA
[2] Mayo Clin, Dept Biostat, Scottsdale, AZ USA
[3] Pharmaessentia, Taipei, Taiwan
[4] Mayo Clin Scottsdale, Phoenix, AZ USA
[5] UT Hlth San Antonio Canc Ctr, San Antonio, TX USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-115521
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5475
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [1] Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs Anagrelide as Second Line Therapy in Essential Thrombocythemia
    Masarova, Lucia
    Komatsu, Norio
    Gill, Harinder
    Jin, Jie
    Lee, Sung-Eun
    Hou, Hsin-An
    Sato, Toshiaki
    Qin, Albert
    Urbanski, Raymond
    Shih, Weichung
    Zagrijtschuk, Oleh
    Zimmerman, Craig
    Mesa, Ruben
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S405 - S405
  • [2] Surpass-ET: Ropeginterferon Alfa-2b (P1101) vs. Anagrelide as Second Line Therapy in Essential Thrombocythemia
    Mesa, Ruben
    Komatsu, Norio
    Gill, Harinder
    Jin, Jie
    Lee, Sung-Eun
    Hou, Hsin-An
    Sato, Toshiaki
    Qin, Albert
    Urbanski, Raymond
    Shih, Weichung
    Zagrijtschuk, Oleh
    Zimmerman, Craig
    Verstovsek, Srdan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S342 - S342
  • [3] Compassionate Use of Ropeginterferon-Alfa-2b/P1101 for Treatment of High Risk Polycythemia Vera and Essential Thrombocythemia Patients Previously Controlled on Pegylated Interferon-Alfa-2a/Pegasys®
    Gilreath, Jeffrey A.
    Tashi, Tsewang
    Kim, Soo Jin
    Hickman, Kimberly
    Prchal, Josef T.
    BLOOD, 2018, 132
  • [4] The Design of a Phase 2 Study to Evaluate the Safety and Efficacy of Ropeginterferon Alfa-2b (P1101) in Chinese Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea (HU)
    Jin, Jie
    Zhang, Lei
    Zhang, Su-Jiang
    Chen, Suning
    Duan, Minghui
    Zhang, Jingjing
    Wang, Wei
    Shen, Warren
    Zagrijtschuk, Oleh
    Urbanski, Raymond
    Qin, Albert
    Xiao, Zhijian
    BLOOD, 2021, 138
  • [5] A Single-Arm Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in North American Adults With Essential Thrombocythemia
    Verstovsek, Srdan
    Mesa, Ruben
    Mascarenhas, John
    Tashi, Tsewang
    Shih, Weichung
    Sato, Toshiaki
    Urbanski, Raymond
    Zagrijtschuk, Oleh
    Zimmerman, Craig
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S342 - S343
  • [6] A Phase 3b, Single-Arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon Alfa-2bNjft (P1101) in Adult Patients with Polycythemia Vera
    Mascarenhas, John
    Zagrijtschuk, Oleh
    Zimmerman, Craig
    Qin, Albert
    Urbanski, Raymond W.
    BLOOD, 2022, 140 : 6748 - 6749
  • [7] A Single-Arm Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in North American Adults With Essential Thrombocythemia
    Masarova, Lucia
    Mascarenhas, John
    Shih, Weichung
    Tashi, Tsewang
    Sato, Toshiaki
    Urbanski, Raymond
    Zagrijtschuk, Oleh
    Zimmerman, Craig
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S405 - S406
  • [8] The Rationale, Design, and Baseline Characteristics of a Phase 2 Study to Evaluate the Safety and Efficacy of Ropeginterferon Alfa-2b (P1101) in Japanese Patients with Polycythemia Vera for Whom the Current Standard of Care Is Difficult to Apply
    Kirito, Keita
    Shimoda, Kazuya
    Takenaka, Katsuto
    Qin, Albert
    Zagrijtschuk, Oleh
    Sato, Toshiaki
    Miyachi, Narihisa
    Kawase, Hiroaki
    Yonezu, Katsuya
    Komatsu, Norio
    BLOOD, 2020, 136
  • [9] Four Weeks Administration Schedule of Ropeginterferon Alfa-2b (AOP2014/P1101) in Polycythemia Very Patients Allows Maintaining of Efficacy with Favorable Toxicity Profile in the Phase I/II Peginvera Stud
    Buxhofer-Ausch, Veronika
    Gisslinger, Heinz
    Thaler, Josef
    Schloegl, Ernst
    Gastl, Gunther
    Wolf, Dominik
    Kralovics, Robert
    Gisslinger, Bettina
    Ban, Sarita
    Egle, Alexander
    Melchardt, Thomas
    Burgstaller, Sonja
    Willenbacher, Ella
    Schalling, Martin
    Krauth, Maria Theresa
    Them, Nicole C. C.
    Zoerer, Michael
    Ammann-Mwathi, Oliver
    Kadlecova, Pavla
    Zagrijtschuk, Oleh
    Klade, Christoph
    Greil, Richard
    BLOOD, 2015, 126 (23)
  • [10] EXCEED-ET: A single-arm multicenter study to assess the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft (P1101) in North American adults with essential thrombocythemia.
    Masarova, Lucia
    Mascarenhas, John
    Qin, Albert
    Shih, Weichung
    Sato, Toshiaki
    Urbanski, Raymond
    Zagrijtschuk, Oleh
    Zimmerman, Craig
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345